KLRA Kailera Therapeutics, Inc.
Company Analysis
Latest News
🟢 Kailera Therapeutics is trading 4.02% up in pre-market with no verified company-specific catalyst
Kailera Therapeutics is trading 4.02% up at $17.07 after gaining 6.56% during the September 1, 2026 regular session and rebounding from recent declines. - No...
🟢 Kailera Therapeutics is trading 5% up today in after-hours trading after consecutive declines
Kailera Therapeutics is trading at $17.20 (+4.81%) after rebounding from consecutive declines, including a 5.00% drop on August 31. • Shares gained 6.56%...
🟢 Kailera Therapeutics is trading 10% up today after consecutive declines
Kailera Therapeutics is trading 10% up at $16.94 after rebounding from consecutive declines. - Shares fell 5% on August 31, 2026. - No clear company-specific...
🟢 Kailera Therapeutics is trading 4.48% up after consecutive declines, with no clear catalyst
Kailera Therapeutics is trading 4.48% up at $16.09 after an intraday rebound following consecutive declines, with no clear company-specific catalyst...
🔴 Kailera Therapeutics is trading 4.07% down today on wider-than-expected second-quarter loss concerns
Kailera Therapeutics is trading 4.07% down now at $15.55, extending the August 28 decline amid concerns about its wider-than-expected second-quarter loss. -...
🔴 Kailera Therapeutics is trading 11.39% down today amid intensified biotech selling ahead of Warsh’s speech
Kailera Therapeutics is trading 11.39% down now at $16.42 as broad biotech-sector selling intensified ahead of Federal Reserve Chair Kevin Warsh’s Jackson Hole...
🔴 Kailera Therapeutics falls 4.5% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Kailera Therapeutics is trading 5% up today amid a broad biotech-sector rally
Kailera Therapeutics is trading 5.26% up now at $17.41, primarily benefiting from a broad biotech-sector rally rather than a confirmed company-specific...
Kailera Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 25, 2026
For the second quarter of 2026, analysts anticipate Kailera Therapeutics will report a consensus net loss of $0.74 per share on zero revenue, with the stock...
🟢 Kailera Therapeutics is trading 4.01% up in pre-market amid firmer Nasdaq futures, no fresh company catalyst
Kailera Therapeutics is trading at $18.16, up 4.01% in pre-market on August 21, 2026, primarily amid stronger broader risk sentiment. - Nasdaq Composite...
🔴 Kailera Therapeutics falls 4.3% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Kailera Therapeutics is trading 4% down today amid biotechnology sector weakness
Kailera Therapeutics is trading 4.02% down now at $17.77 as biotechnology shares weaken and broader risk appetite fades. - The biotechnology sector fell 4.03%...
🟢 Kailera Therapeutics is trading 8.1% up in pre-market after August 12 report details obesity-pipeline progress
Kailera Therapeutics is trading at $20.01 (+8.1%) in pre-market after its August 12, 2026 second-quarter report outlined obesity-pipeline progress. • The...
🟢 Kailera Therapeutics is trading 4% up today after its second-quarter report
Kailera Therapeutics is trading 4.01% up at $18.66 as investors continue digesting its August 12, 2026 second-quarter report and business updates. - Reported...
RTW Investments takes 8.3% stake in Kailera, backing obesity drug developer
RTW Investments disclosed an 8.3% passive stake in Kailera Therapeutics, Inc. The healthcare investment firm reported the position in a Schedule 13G filing...
Kailera Rallied on Its Obesity Pipeline — But Can a Pre-Revenue Biotech Burning $111 Million a Quarter Justify the Bet?
Shares shifted as Kailera Therapeutics jumped 6.9% to $19.88 the morning after its second-quarter report landed a mix of ugly losses and promising drug...
🟢 Kailera Therapeutics is trading 6.94% up in pre-market after progress toward global Phase 3 obesity trials
Kailera Therapeutics is trading 6.94% up now in pre-market at $19.88 after its August 12, 2026, second-quarter report highlighted progress toward global Phase...
Kailera Therapeutics second quarter 2026 net loss widens to $111M while obesity pipeline advances
Kailera Therapeutics reported a significant expansion in net loss for the second quarter of 2026, primarily driven by a 418% year-over-year increase in...
🟢 Kailera Therapeutics is trading 5.94% up in pre-market after announcing CTO appointment
Kailera Therapeutics is trading 5.94% up in pre-market at $19.99 after announcing Nur Nicholson as chief technology officer on August 11, 2026, effective...
🟢 Kailera Therapeutics is trading 6.06% up in pre-market possibly ahead of August 12 earnings
Kailera Therapeutics is trading 6.06% up at $19.79 in pre-market, with positioning ahead of its August 12 second-quarter 2026 earnings a possible factor. -...